Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts rate Cabaletta Bio a "Moderate Buy" — seven brokers cover the stock (six buy, one sell) with an average 1-year price target of $17, versus the current share price around $3.13.
• Insider buying has increased: CEO Steven Nichtberger bought 45,000 shares at $2.24 and Director Mark Simon bought 11,061 shares at $2.28; insiders purchased 127,668 shares (~$286k) in the last 90 days and now own 11.25% of the company.
• Cabaletta is a clinical-stage biotech developing CAAR‑T therapies (lead candidate DSG3‑CAART); it reported Q EPS of -$0.40 (beating -$0.45) and has a market cap of about $348 million with a 52‑week range of $1.06–$3.78.

Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $17.00.

Several research analysts have recently issued reports on the company. Morgan Stanley decreased their target price on Cabaletta Bio from $14.00 to $13.00 and set an "overweight" rating for the company in a research report on Tuesday, March 24th. Wall Street Zen raised Cabaletta Bio from a "strong sell" rating to a "hold" rating in a research report on Sunday, March 29th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Finally, Guggenheim increased their target price on Cabaletta Bio from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th.

Insider Buying and Selling

In related news, CEO Steven Nichtberger acquired 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the transaction, the chief executive officer directly owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. This represents a 4.56% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Simon acquired 11,061 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The shares were bought at an average cost of $2.28 per share, with a total value of $25,219.08. Following the transaction, the director owned 147,205 shares in the company, valued at $335,627.40. This represents a 8.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 127,668 shares of company stock worth $286,211 in the last 90 days. Corporate insiders own 11.25% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CABA. China Universal Asset Management Co. Ltd. bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $34,000. CRA Financial Services LLC increased its position in Cabaletta Bio by 36.4% during the 3rd quarter. CRA Financial Services LLC now owns 15,000 shares of the company's stock valued at $35,000 after buying an additional 4,000 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $38,000. Clear Harbor Asset Management LLC bought a new position in Cabaletta Bio during the 4th quarter valued at approximately $43,000. Finally, Jones Financial Companies Lllp bought a new position in Cabaletta Bio during the 3rd quarter valued at approximately $47,000.

Cabaletta Bio Stock Performance

Shares of NASDAQ:CABA opened at $3.13 on Monday. Cabaletta Bio has a 52-week low of $1.06 and a 52-week high of $3.78. The firm has a market capitalization of $348.43 million, a P/E ratio of -1.37 and a beta of 3.30. The stock has a 50 day moving average price of $2.96 and a 200-day moving average price of $2.63.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its earnings results on Monday, March 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.05. On average, equities analysts forecast that Cabaletta Bio will post -2.34 EPS for the current fiscal year.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.